MedTrace Logo

Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package

NCT05683873 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2025-01-28

No results posted yet for this study

Summary

The aim of this study is to analyze the relationship between the blood biomarker GDF-15 and heart damage after stroke.

It is being conducted in France, in the Neurology Department of the Dijon University Hospital (Burgundy). The research is interventional because a biological blood test will be performed, as well as a heart rhythm recording and several cardiac echograms during the hospitalization of the participants and during the follow-up consultation scheduled 4 to 6 months after the stroke.

A total of 130 stroke patients will participate in this study.

Participation includes 4 visits:

* Inclusion visit (within 24 hours of the first stroke symptoms)
* visit 1 (within 24 to 72 hours of stroke)
* visit 2 (within 48 hours of visit 1)
* Visit 3 (approximately 4-6 months post-stroke)

Conditions

Interventions

PROCEDURE

Electrocardiogram

Inclusion visit, V1, V2 and V3

PROCEDURE

transthoracic echocardiography

V1, V2 and V3

BIOLOGICAL

standard biology

Inclusion visit

BIOLOGICAL

determination of serum GDF-15, osteoprotegerin and ST-2

Inclusion visit, V1, V2 and V3

BIOLOGICAL

Ultrasensitive Troponin-Ic

Inclusion visit, V1, V2 and V3

OTHER

Collection of clinical and radiological data

Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data

OTHER

72-hour continuous Holter-ECG recording

V1

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-13
Primary Completion
2027-08-31
Completion
2027-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05683873 on ClinicalTrials.gov